iHuman released FY2024 Q3 earnings on December 26 (EST) with actual revenue of 34.15 M USD and EPS of 0.0641 USD
Brief Summary
iHuman reported Q3 2024 revenues of $34.15 million and an EPS of $0.0641.
Impact of The News
Financial Performance Overview: iHuman’s Q3 2024 revenue was $34.15 million, with an EPS of $0.0641, slightly below the earlier reported EPS of $0.07 by ZacksMarket Beat+ 2. The revenue represents a decrease of approximately 8.4% compared to the same period last year, suggesting a contraction in business activityprnewswire+ 2.
Market Expectations and Comparison: The reported EPS of $0.0641 is lower than the $0.07 reported by Zacks, indicating a slight miss from market expectationsMarket Beat. However, the company maintains a respectable net profit margin of 13.72% and a return on equity of 14.17%Market Beat.
Peer Benchmarking: In comparison to its peers, iHuman’s performance is modest, considering its P/E ratio of 5.17, which suggests a relatively undervalued position in the marketMarket Beat.
Business Implications and Future Outlook: The decrease in revenue and EPS below market expectations could indicate potential challenges such as market saturation or increased competition. However, iHuman’s stable ROE and net profit margin imply operational efficiency. The company may need to explore avenues for growth, such as expanding its user base or innovating its product offerings to improve future financial performance. Investors should monitor the company’s strategies to counteract the declining revenue trend and its impact on stock performance.
